Investment Rating - The report maintains a "Buy" rating for Zai Lab (09688.HK) [2] Core Views - Zai Lab's drug Efgartigimod shows strong potential in the treatment of Myasthenia Gravis (MG) with rapid onset and long-term efficacy, establishing its position as a Best-in-Class (BIC) therapy [8][11] - The FDA has approved the pre-filled subcutaneous injection form of Efgartigimod, enhancing its competitive edge in the market [25][26] - The company is expected to achieve significant revenue growth, with projected revenues of $564 million in 2025 and $1.357 billion in 2027, reflecting growth rates of 41.35% and 62.46% respectively [7][40] Summary by Sections Market Performance - Zai Lab's stock price is currently at HKD 22.20, with a market capitalization of HKD 24.45 billion [2][7] Financial Data and Forecast - Total shares outstanding: 1,101.28 million - Revenue projections: $267 million in 2023, $399 million in 2024, $564 million in 2025, $835 million in 2026, and $1.357 billion in 2027 - Net profit projections: -$335 million in 2023, -$257 million in 2024, -$166 million in 2025, $17 million in 2026, and $168 million in 2027 - Gross margin expected to improve from 62.94% in 2024 to 69.45% in 2027 [7][40] Drug Development Insights - Efgartigimod has shown rapid efficacy in clinical trials, with 40% of patients achieving minimal symptom expression (MSE) within the first treatment cycle [8][14] - Long-term studies indicate consistent efficacy and safety, with 89% of patients showing significant improvement after 11 treatment cycles [21][22] - The drug is positioned to treat multiple autoimmune diseases, expanding its market potential beyond MG [37][32] Competitive Landscape - Despite the emergence of several competing biologics in the MG treatment space, Efgartigimod's sales growth remains robust, with projected global sales of approximately $2.2 billion in 2024 [32][34]

[Table_Main] 证券研究报告 | 公司点评 再鼎医药(09688.HK) 2025 年 04 月 14 日 买入（维持） 所属行业：医疗保健业/药品及生物科技 当前价格(港币)：22.20 元 证券分析师 周新明 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn 李霁阳 资格编号：S0120523080003 邮箱：lijy7＠tebon.com.cn 市场表现 -31% 0% 31% 63% 94% 126% 157% 188% 2024-04 2024-08 2024-12 再鼎医药 恒生指数 | 恒 生 指 数 对 | 1M | 2M | 3M | | --- | --- | --- | --- | | 比 | | | | | 绝对涨幅(%) | -18.83 | 5.21 | 17.34 | | 相对涨幅(%) | -7.45 | 9.53 | 7.63 | | 资料来源：德邦研究所，聚源数据 | | | | 重症肌无力领域近期新药进展众多，我们认为艾加莫德作为 BIC，在 MG 治疗领 域地位难以被撼动。 1）快速起效，快速达标：越来越多的临床试验使用基 ...

资格编号：S0120524100001 邮箱：wanghb3＠tebon.com.cn 研究助理 郝逸璇 [Table_Main] 证券研究报告 | 行业点评 基础化工 优于大市（维持） 证券分析师 王华炳 邮箱：haoyx＠tebon.com.cn 市场表现 -26% -17% -9% 0% 9% 17% 26% 2024-04 2024-08 2024-12 基础化工 沪深300 资料来源：德邦研究所，聚源数据 相关研究 1.《新凤鸣(603225.SH)：周而复始周 期新，凤鸣长空启华章》，2025.3.3 2.《桐昆股份(601233.SH)：静待桐花 映 日 开 ， 方 得 昆 玉 照 朝 晖 》， 2025.1.27 3.《涤纶长丝深度报告：供需预期再 纠偏，周期弹性被低估》，2025.1.10 4.《涤纶长丝行业更新：高质量发展 倡议出台，看好长周期格局优化》， 2024.12.22 涤纶长丝行业更新：油价风险释 放&需求预期改善，龙头估值有 望修复 [Table_Summary] 投资要点： 事件：①当地时间 4 月 9 日，特朗普宣布将对未实施报复性关税措施的 75 个国家 和地区暂停征收对 ...

[Table_Main] 证券研究报告 | 行业周报 医药生物 2025 年 04 月 13 日 医药生物 优于大市（维持） 证券分析师 周新明 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn 安柯 资格编号：S0120524060006 邮箱：anke＠tebon.com.cn 市场表现 -22% -15% -7% 0% 7% 15% 22% 2024-04 2024-08 2024-12 医药生物 沪深300 数据来源：聚源数据，德邦研究所 相关研究 1.《医药行业周报：中国创新药逐 步进入收获期，关注技术革新与 BD 潜力》，2025.4.6 2.《医药行业周报：减肥赛道持续 景气，关注信达生物、博瑞医药、 歌礼制药等》，2025.3.30 3.《医药行业周报：生命科学产业 链需求端逐步回暖，关注并购催 化，关注毕得医药、泰坦科技等》， 2025.3.23 4.《医药行业周报：流动性改善+基 本面反转，看好港股高值耗材后续 行情，重点关注归创通桥、心泰医 疗、微创脑科学等》，2025.3.17 5.《昆药集团 2024 年报点评：核心 品种快速增长，品牌+渠道建设稳 ...

王华炳 资格编号：S0120524100001 邮箱：wanghb3＠tebon.com.cn [Table_Main] 证券研究报告 | 行业点评 基础化工 优于大市（维持） 证券分析师 研究助理 郝逸璇 邮箱：haoyx＠tebon.com.cn 市场表现 -26% -17% -9% 0% 9% 17% 26% 2024-04 2024-08 2024-12 基础化工 沪深300 资料来源：德邦研究所，聚源数据 相关研究 1.《新凤鸣(603225.SH)：周而复始周 期新，凤鸣长空启华章》，2025.3.3 2.《桐昆股份(601233.SH)：静待桐花 映 日 开 ， 方 得 昆 玉 照 朝 晖 》， 2025.1.27 3.《涤纶长丝深度报告：供需预期再 纠偏，周期弹性被低估》，2025.1.10 4.《涤纶长丝行业更新：高质量发展 倡议出台，看好长周期格局优化》， 2024.12.22 涤纶长丝行业更新：油价风险释 放&需求预期改善，龙头估值有 望修复 [Table_Summary] 投资要点： 事件：①当地时间 4 月 9 日，特朗普宣布将对未实施报复性关税措施的 75 个国家 和地区暂停征收对 ...

医药生物 优于大市（维持） 证券分析师 周新明 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn [Table_Main] 证券研究报告 | 行业周报 医药生物 2025 年 04 月 13 日 安柯 资格编号：S0120524060006 邮箱：anke＠tebon.com.cn 市场表现 -22% -15% -7% 0% 7% 15% 22% 2024-04 2024-08 2024-12 医药生物 沪深300 数据来源：聚源数据，德邦研究所 相关研究 1.《医药行业周报：中国创新药逐 步进入收获期，关注技术革新与 BD 潜力》，2025.4.6 2.《医药行业周报：减肥赛道持续 景气，关注信达生物、博瑞医药、 歌礼制药等》，2025.3.30 3.《医药行业周报：生命科学产业 链需求端逐步回暖，关注并购催 化，关注毕得医药、泰坦科技等》， 2025.3.23 4.《医药行业周报：流动性改善+基 本面反转，看好港股高值耗材后续 行情，重点关注归创通桥、心泰医 疗、微创脑科学等》，2025.3.17 5.《昆药集团 2024 年报点评：核心 品种快速增长，品牌+渠道建设稳 ...

[Table_Main] 2025 年 04 月 13 日 范式更迭 [Table_Summary] 投资要点： 请务必阅读正文之后的信息披露和法律声明 海外市场周报 证券分析师 薛威 资格编号：S0120523080002 邮箱：xuewei＠tebon.com.cn 谭诗吟 资格编号：S0120523070007 邮箱：tansy＠tebon.com.cn 证券研究报告 | 海外市场周报 上周全球股市涨少跌多。美股三大指数领涨，纳指、标普 500 和道指涨跌幅分别 为+7.3%、+5.7%和+5.0%；欧洲市场三大主要指数集体回调；亚太地区仅越南 VN30 指数上涨，其余市场都出现不同程度的回调。 股债汇三杀下，关税有所缓和。上周美元资产集体"滑铁卢"，继美股持续下行之 后，美元指数加速跌破 100 关口，美债利率连续飙升，10 年期美债收益率一度接 近 4.6%的位置，这还是在美国 3 月 CPI 数据弱于预期的背景下，剔除食品和能源 价格后的核心 CPI 同比上涨 2.8%，连续第二个月回落，且创 2021 年 3 月以来最 低水平，但我们认为后续关税影响或抬升未来几个月的核心通胀。对过去若干年处 于 ...

Market Performance - Global stock markets experienced mixed results last week, with the US indices leading gains: Nasdaq up by 7.3%, S&P 500 up by 5.7%, and Dow Jones up by 5.0%[3] - European markets saw a collective pullback, while only Vietnam's VN30 index recorded an increase, with other markets experiencing varying degrees of decline[3] Economic Indicators - The US dollar index fell below the 100 mark, and the 10-year US Treasury yield approached 4.6%, despite March CPI data being weaker than expected[3] - Core CPI, excluding food and energy, rose by 2.8% year-on-year, marking the lowest level since March 2021[3] Tariff Adjustments - The Trump administration eased tariffs, implementing a 90-day suspension of tariffs for countries that do not retaliate, reducing tariffs to 10% during this period[3] - The Customs and Border Protection (CBP) agency updated guidelines to exempt certain products from "reciprocal tariffs" and reported system issues for tariff exemptions[3] Dollar Confidence - The report questions whether the recent tariff adjustments can restore confidence in the US dollar, which has been impacted by the tariff increases aimed at addressing US fiscal issues[3] - The potential for a shift from a "dollar-centric" market to a new paradigm where non-US currencies like the euro, yen, pound, and yuan gain prominence is highlighted[3] Investment Strategy - It is recommended to reduce exposure to US dollar assets and increase allocations to non-US assets, particularly in European, Japanese, Hong Kong, and Indian markets[3] - The volatility in financial markets presents opportunities for reallocation and diversification[3] Risk Factors - Risks include potential unexpected rebounds in overseas inflation, weaker-than-expected global economic conditions, and escalated geopolitical tensions that could lead to market volatility[3]

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has underperformed the market recently, with a decline of 5.1% compared to the Shanghai Composite Index's decline of 3.1% during the week of April 3 to April 11, 2025 [6][17] - The price of fatty alcohol has seen a significant increase, with an average market price of 24,500 RMB/ton as of April 11, 2025, reflecting a month-on-month increase of 13.4% and a year-on-year increase of 81.5% [27][28] - Supply-side issues are prevalent in the fatty alcohol sector, with several production facilities undergoing maintenance, leading to a tightening supply situation [29] Summary by Sections 1. Core Viewpoints - The report highlights that the basic chemical industry is entering a new long-term growth cycle, driven by policy support and improving supply-demand dynamics [14] - The report suggests focusing on investment opportunities in the fatty alcohol supply chain, particularly due to rising prices and demand stability in downstream applications [29] 2. Overall Performance of the Chemical Sector - The basic chemical industry index has decreased by 5.1% in the recent week, ranking 17th among 31 industry sectors [6][17] - Year-to-date, the basic chemical industry index has outperformed both the Shanghai Composite Index and the ChiNext Index [17] 3. Individual Stock Performance in the Chemical Sector - Among 426 stocks in the basic chemical sector, 72 stocks increased while 354 stocks decreased in value during the recent week [25] - The top-performing stocks included Runpu Food (+47%) and Quartz Co. (+42%) [26] 4. Key News and Company Announcements - The report notes that the supply of fatty alcohol is expected to tighten further, with significant production capacity scheduled for maintenance [27] - Companies like Juhua Co. and Tongyi Zhong are projected to report substantial profit increases in Q1 2025, driven by strong market demand and price increases in their core products [30][31]

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has underperformed the market recently, with a decline of 5.1% in the industry index compared to a 3.1% drop in the Shanghai Composite Index during the week of April 3 to April 11 [6][17] - The report highlights a significant increase in the price of fatty alcohol, which reached an average of 24,500 CNY/ton, up 800 CNY/ton from the previous trading day, marking a month-on-month increase of 13.4% and a year-on-year increase of 81.5% [27][28] - Supply-side issues are expected to persist due to frequent maintenance of fatty alcohol production facilities and a rigid demand from downstream surfactant sectors [29] Summary by Sections 1. Core Viewpoints - The report emphasizes that the chemical industry is entering a new long-term prosperity cycle, driven by policy support and supply-side reforms [14] - Key investment themes include focusing on core assets, industries facing supply constraints, and sectors with upward demand certainty [15][16] 2. Overall Performance of the Chemical Sector - The basic chemical industry index has decreased by 5.1% in the recent week, ranking 17th among 31 industry sectors [17] - Year-to-date, the basic chemical industry index has outperformed both the Shanghai Composite and the ChiNext indices [17] 3. Individual Stock Performance in the Chemical Sector - Among 426 stocks in the basic chemical sector, 72 stocks rose while 354 fell during the week [25] - The top gainers included companies like Runpu Food (+47%) and Quartz Co. (+42%), while the biggest losers included Xiangyuan New Materials (-21.6%) and Yongli Co. (-19.8%) [26] 4. Key News and Company Announcements - The report notes that the supply of fatty alcohol is tightening, with significant production capacity expected to be offline soon [27] - Companies like Juhua Co. and Tongyi Zhong are projected to see substantial profit increases in Q1 2025 due to rising prices and stable operations [30][31]